CLAIMS:

1. An anti-RSV antibody or antigen-binding fragment thereof, wherein:

RSV does not produce a virus that escapes neutralization by the antibody or antigen-binding fragment thereof after more than 10 or more rounds of viral replication in the presence of the antibody or antigen-binding fragment thereof.

~~2. The anti-RSV antibody or antigen-binding fragment thereof of claim 1~~, wherein:

the antibody or antigen-binding fragment comprises:

a variable heavy chain containing a VH CDR1 comprising the sequence of amino acid residues set forth in SEQ ID NO:405 or 437 or a sequence of amino acids having at least or at least ~~about~~ 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:405 or 437; a VH CDR2 comprising the sequence of amino acid residues set forth in SEQ ID NO: 406 or a sequence of amino acids having at least or at least ~~about~~ 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:406; and a VH CDR3 comprising the sequence of amino acid residues set forth in SEQ ID NO:407 or a sequence of amino acids having at least or at least ~~about~~ 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:407; and

a variable light chain containing a VL CDR1 comprising the sequence of amino acids set forth in SEQ ID NO: 408 or a sequence of amino acids having at least or at least ~~about~~ 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:408; a VL CDR2 comprising the sequence of amino acids set forth in SEQ ID NO:409 or a sequence of amino acids having at least or at least ~~about~~ 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:409; and a VL CDR3 comprising the sequence of amino acids set forth in SEQ ID NO:410 or a sequence of amino acids having at least or at least ~~about~~ 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:410; and

the antibody or antigen-binding fragment thereof immunospecifically binds to Respiratory Syncytial Virus (RSV) fusion (F) protein and/or neutralizes RSV.

~~3~~2. The anti-RSV antibody or antigen-binding fragment of claim 1 ~~or 2~~, comprising:

a VH domain, wherein the amino acid sequence of the VH domain is set forth in amino acids 1-121 of SEQ ID NO:396 or is at least or ~~about~~ 80%, 81%, 82%, 83%, 84%, 85%, 86%,

87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in amino acids 1-121 of SEQ ID NO:396; and

a VL domain, wherein the amino acid sequence of the VL domain is set forth in amino acids 1-110 of SEQ ID NO:395 or is at least or ~~about~~ 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in amino acids 1-110 of SEQ ID NO:395.

~~4. An anti-RSV antibody or antigen-binding fragment thereof, wherein:~~

~~the antibody or antigen-binding fragment comprises:~~

~~a variable heavy chain containing a VH CDR1 comprising the sequence of amino acid residues set forth in SEQ ID NO:464 or 483 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:464 or 483; a VH CDR2 comprising the sequence of amino acid residues set forth in SEQ ID NO: 465 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:465; and a VH CDR3 comprising the sequence of amino acid residues set forth in SEQ ID NO:466 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:466; and~~

~~a variable light chain containing a VL CDR1 comprising the sequence of amino acids set forth in SEQ ID NO: 467 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:467; a VL CDR2 comprising the sequence of amino acids set forth in SEQ ID NO:468 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:468; and a VL CDR3 comprising the sequence of amino acids set forth in SEQ ID NO:469 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:469; and~~

~~the antibody or antigen-binding fragment immunospecifically binds to Respiratory Syncytial Virus (RSV) fusion (F) protein and/or neutralizes RSV.~~

~~5. The anti-RSV antibody or antigen-binding fragment of claim 4, comprising:~~

~~a VH domain, wherein the amino acid sequence of the VH domain is set forth in amino acids 1-133 of SEQ ID NO:454 or is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%,~~

87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in amino acids 1-133 of SEQ ID NO:454; and

a VL domain, wherein the amino acid sequence of the VL domain is set forth in amino acids 1-107 of SEQ ID NO:455 or is at least or about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in amino acids 1-107 of SEQ ID NO:455.

6. An anti-RSV antibody or antigen-binding fragment thereof, wherein:

the antibody or antigen-binding fragment comprises a variable heavy chain containing a VH CDR1 comprising the sequence of amino acid residues set forth in SEQ ID NO:458 or 482 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:458 or 482; a VH CDR2 comprising the sequence of amino acid residues set forth in SEQ ID NO: 459 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:459; and a VH CDR3 comprising the sequence of amino acid residues set forth in SEQ ID NO:460 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:460; and

a variable light chain containing a VL CDR1 comprising the sequence of amino acids set forth in SEQ ID NO: 461 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:461; a VL CDR2 comprising the sequence of amino acids set forth in SEQ ID NO:462 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:462; and a VL CDR3 comprising the sequence of amino acids set forth in SEQ ID NO:463 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:463; and

the antibody or antigen-binding fragment immunospecifically binds to Respiratory Syncytial Virus (RSV) fusion (F) protein and/or neutralizes RSV.

7. The anti-RSV antibody or antigen-binding fragment of claim 6, wherein the antibody or antigen-binding fragment comprises a VH domain, wherein the amino acid sequence of the VH domain is set forth in amino acids 1-124 of SEQ ID NO:452 or is at least or about

identity to SEQ ID NO:417 or 439; a VH CDR2 comprising the sequence of amino acid residues set forth in SEQ ID NO: 418 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:418; and a VH CDR3 comprising the sequence of amino acid residues set forth in SEQ ID NO:419 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:419; and

a variable light chain containing a VL CDR1 comprising the sequence of amino acids set forth in SEQ ID NO: 420 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:420; a VL CDR2 comprising the sequence of amino acids set forth in SEQ ID NO:421 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:421; and a VL CDR3 comprising the sequence of amino acids set forth in SEQ ID NO:422 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:422;

c) a variable heavy chain containing a VH CDR1 comprising the sequence of amino acid residues set forth in SEQ ID NO:423 or 440 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:423 or 440; a VH CDR2 comprising the sequence of amino acid residues set forth in SEQ ID NO: 424 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:424; and a VH CDR3 comprising the sequence of amino acid residues set forth in SEQ ID NO:425 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:425; and

a variable light chain containing a VL CDR1 comprising the sequence of amino acids set forth in SEQ ID NO: 426 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:426; a VL CDR2 comprising the sequence of amino acids set forth in SEQ ID NO:427 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:427; and a VL CDR3 comprising the sequence of amino acids set forth in SEQ ID NO:428 or a sequence of amino

acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:428;

d) a variable heavy chain containing a VH CDR1 comprising the sequence of amino acid residues set forth in SEQ ID NO:429 or 441 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:429 or 441; a VH CDR2 comprising the sequence of amino acid residues set forth in SEQ ID NO: 430 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:430; and a VH CDR3 comprising the sequence of amino acid residues set forth in SEQ ID NO:431 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:431; and

a variable light chain containing a VL CDR1 comprising the sequence of amino acids set forth in SEQ ID NO: 432 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:432; a VL CDR2 comprising the sequence of amino acids set forth in SEQ ID NO:433 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:433; and a VL CDR3 comprising the sequence of amino acids set forth in SEQ ID NO:434 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:434;

and

e) a variable heavy chain containing a VH CDR1 comprising the sequence of amino acid residues set forth in SEQ ID NO:470 or 484 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:470 or 484; a VH CDR2 comprising the sequence of amino acid residues set forth in SEQ ID NO: 471 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:471; and a VH CDR3 comprising the sequence of amino acid residues set forth in SEQ ID NO:472 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:472; and

~~a variable light chain containing a VL CDR1 comprising the sequence of amino acids set forth in SEQ ID NO: 473 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:473; a VL CDR2 comprising the sequence of amino acids set forth in SEQ ID NO:474 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:474; and a VL CDR3 comprising the sequence of amino acids set forth in SEQ ID NO:475 or a sequence of amino acids having at least or at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:475; and~~

~~the antibody or antigen-binding fragment immunospecifically binds to Respiratory Syncytial Virus (RSV) fusion (F) protein and/or neutralizes RSV.~~

~~9~~3. The antibody or antigen-binding fragment of ~~any of~~ claim~~s~~ 1~~-8~~ or 2, wherein the antibody or antigen-binding fragment has an EC_{50} of less than 2 nM for neutralization of RSV in an *in vitro* plaque reduction assay or an affinity of at least 10^8 M^{-1} for isolated RSV F protein or for RSV virus.

~~10~~4. A multivalent antibody, comprising:

a first antigen-binding portion comprising an antibody or antigen-binding fragment of ~~any of~~ claim~~s~~ 1~~-9~~ or 2~~or an antigen-binding fragment thereof~~ conjugated to a multimerization domain; and

a second antigen-binding portion comprising an antigen-binding fragment of an antiviral antibody conjugated to a second multimerization domain, wherein:

the first multimerization domain and the second multimerization domain are complementary or the same, whereby the first antigen-binding portion and second antigen-binding portion form a multivalent antibody.

~~11~~5. A pharmaceutical composition comprising:

an antibody or antigen-binding fragment of ~~any of~~ claim~~s~~ 1~~-9~~ or 2, or the multivalent antibody of claim ~~10~~4, and a pharmaceutically acceptable carrier or excipient.

~~12~~6. An antibody or antigen-binding fragment of ~~any of~~ claim~~s~~ 1~~-9~~ or 2 for treating or inhibiting one or more symptoms of a RSV infection, or for preventing a RSV infection.

~~13~~7. Use of an antibody or antigen-binding fragment of ~~any of~~ claims 1~~-9~~ or 2 for formulation of a medicament for treating or inhibiting one or more symptoms of a RSV infection, or for preventing a RSV infection.

~~14~~8. A method of detecting RSV infection comprising:

(a) assaying the level of RSV antigen in a fluid, cell, or tissue sample using an antibody or antigen-binding fragment of ~~any of~~ claims 1~~-9~~ or 2;

(b) comparing the assayed level of RSV antigen with a control level whereby an increase in the assayed level of RSV antigen compared to the control level of the RSV antigen is indicative of a RSV infection.

~~15~~9. An isolated nucleic acid that encodes the antibody or antigen-binding fragment of ~~any of~~ claims 1~~-9~~ or 2.